A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumor microenvironment or improve clinical outcomes.